Abstract
Introduction
Metabolic syndrome (MetS) is comprised of a group of risk factors for type 2 diabetes and cardiovascular diseases, including insulin resistance, abdominal obesity, dyslipidemia, blood pressure, and impaired fasting glucose [1] . The most common clinical manifestations of MetS include: abdominal obesity, hypertriglyceridaemia, reduced high-density lipoprotein cholesterol (HDL-C), hyperglycaemia, and high blood pressure (BP) [2] . MetS is responsible for a three-fold increase in the risk of atherosclerotic cardiovascular diseases (CVDs) and increased mortality from CVD, as well as all-causes, compared to the general population [3] . MetS is also associated with a fourfold increased relative risk of developing diabetes [4, 5] . There are eight commonly used definitions for MetS, but the National Cholesterol Education ProgrammeAdult Treatment Panel III (NCEP ATP III) and the International Diabetes Federation (IDF) definitions are the most commonly used [6] . These definitions have many similarities, but they differ on several components and on the cut-off points used (Table 1) .
Therefore, although we could expect slight differences in prevalence rates, according to the criteria used in each study, genetic and geographical differences may also contribute to differences in the rates of MetS. For example, using the ATP III definition, Ford et al. reported the prevalence rate of metabolic syndrome in the USA to be 34.3% [3] , while Tillin et al. reported the age-adjusted rates were 18.4% for men and 14.4% for women among Europeans, 28.8% for men and 31.8% for women in South Asians, and 15.5% for men and 23.4% for women in African-Caribbeans. Further, the prevalence rate was reported to be 15.7% in Taiwan, using the same criteria [7, 8] .
Rheumatoid arthritis (RA) is a chronic inflammatory disorder of unknown etiology [9] that has a prevalence rate of approximately 0.5 to 1% [10] . Rheumatoid arthritis and metabolic syndrome are considered to be diseases with common traits that can increase the risk of cardiovascular disease [11] , with previous research showing an association between the two [12] . Higher frequencies of insulin resistance and MetS have been reported in patients with RA [12, 13] , with the frequency of MetS in RA patients ranging from 14 to 56% [14] . This variation can be explained by differences in the definition of MetS, along with differences in ethnicity, geographic area, study design, and study population. However, although many studies have reported a higher prevalence of MetS among RA patients, compared to the general population [15, 16] , a number of studies have reported a higher prevalence of MetS in the healthy controls [2] .
Research measuring the prevalence of MetS in RA patients has resulted in a wide range of estimates across the world. In addition, research measuring the prevalence of metabolic syndrome using a large sample size is rare. Furthermore, there have been very few meta-analyses on the prevalence of MetS in patients with rheumatoid arthritis [11] . Therefore, the present study aimed to: 1) determine the prevalence of MetS, and its components, in RA patients across the world 2) update the odds ratio of MetS in RA patients, compared to healthy controls, using a comprehensive systematic review and meta-analysis.
Methods

Search strategy and study selection
The current systematic review and meta-analysis was conducted according to PRISMA guidelines [17] . A systematic review was undertaken of English-language medical literature published between January 2000 and August 2016 to identify scientific papers reporting the prevalence and risk of metabolic syndrome and its components (i.e., waist circumference-WC, blood pressure-BP, high-density lipoprotein cholesterol -HDL-C, Triglycerides-TG, fasting blood sugar-FBS) among rheumatoid arthritis patients. International databases, including: the Web of Science, Medline, Scopus, Embase, CABI, CINAHL, DOAJ, Index Medicus for Eastern Mediterranean Region-IMEMR and Google Scholar were searched using the following medical subject headings (MeSH): "Metabolic Syndrome", "Dysmetabolic Syndrome", "Cardiovascular Syndrome", and "Insulin Resistance Syndrome", combined with "Rheumatoid Arthritis", "Prevalence", "Odds Ratio", "Comparative Cross-sectional Studies" and "case-control studies". The search strategy for Medline was developed first and then adapted for the remaining databases. More detailed information regarding the search strategy is presented in Box 1. The grey literature were searched using Google Scholar, as recommended [18] , using the abovementioned search strategy. An expert in this field was also consulted to identify additional papers.
All publications were categorized using Endnote X6. The title and abstract of identified publications were systematically screened and full texts were obtained for those which passed the initial screening. All full text publications were then independently evaluated by two reviewers (SS and JH) for inclusion in the review. Disagreements between the reviewers were resolved by consensus using a third expert (MN). In this study, blinding and task separation were also applied to study selection. All English language observational (cross-sectional and comparative cross-sectional) studies on the prevalence of metabolic syndrome were included in the current study if they clearly described the date of data collection and study location, used appropriate sampling strategies, and conducted appropriate statistical analyses. Case studies and letters to the editor were excluded, along with systematic reviews or meta-analyses. Lastly, studies undertaken on patients with other disorders were also excluded.
Data extraction and quality assessment
Study characteristics (first author's name, date of publication, and country of origin), participant characteristics (gender, age, and sample size), and MetS prevalence (based on the different criteria) were extracted using the full text reviews. The quality of each included study was also assessed using the STROBE checklist [19] .
Statistical analysis
All statistical analyses were undertaken using Review Manager (RevMan) Version 5.3. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The prevalence of metabolic syndrome, and its five components, among rheumatoid arthritis patients were pooled using a random-effects model and presented in a forest plot. The odds ratios for metabolic syndrome in rheumatoid arthritis patients, based upon the different diagnostic criteria, in comparative cross-sectional studies were also pooled using a random-effects model and presented in a forest plot. Statistical heterogeneity was assessed using the I 2 index and a randomeffects model was used when the I 2 index was > 0.6. Stata software version 13 (Stata Corp, College Station, TX, USA) was used to determine which factors were responsible for any observed heterogeneity using meta-regression. Publication bias, with regards to the ORs between MetS and RA was assessed using a Funnel plot and Begg's correlation test [20] .
Results
After removing duplicates, our primary search found 237 relevant articles. Following the exclusion of all non-eligible studies a total of 70 cross-sectional studies and 43 comparative cross-sectional studies, from 25 countries, were retained to estimate the prevalence and risk of metabolic syndrome among RA patients. The details of our study selection method are shown in Fig 1. The majority of the studies reporting MetS prevalence (55 studies) included both male and female patients who were aged >18 years. The lowest and highest prevalence of MetS in rheumatoid arthritis patients reported were 10.6% and 55.5%, respectively. More detailed information about each included studies can be found in Table 2 . The estimated pooled prevalence, with 95% confidence interval (the diamond below the graph shows the pooled prevalence and the horizontal lines define the reported 95% confidence interval in each study) are presented in graphs by gender and by MetS definition.
Total MetS prevalence in RA patients by gender
Using a random effects model, the estimated worldwide prevalence rate of MetS among RA patients was 30.65% (95% CI: 27.87-33.43) (Fig 2) . In addition, information on the prevalence of MetS by gender was available from 19 studies for males and 30 for females. The prevalence rates among males was 31.94% (95% CI: 24.37-39.51) and for females this was 33.03% (95% CI: 28.09-37.97) (Figs 3 and 4). Worldwide prevalence and risk of metabolic syndrome in rheumatoid arthritis patients 
MetS prevalence in RA patients by criteria/definition
Risk of MetS in rheumatoid arthritis patients by criteria/definition
In this section the prevalence of MetS in RA patients and among healthy controls were compared (Table 3 ). The pooled estimates identified a significant positive association between rheumatoid arthritis and the risk of MetS (OR = 1.44; 95% CI: 1.20-1.74). The odds ratios for (Fig 6) .
Publication bias
In order to assess publication bias in relation to the OR for MetS and RA, funnel plots and Begg's correlation were used. These found no evidence of any publication bias (Fig 7) .
Meta-regression
To assess the sources of heterogeneity, four variables were included in a univariable metaregression. Our results indicated that the study date (P = 0.60) and country (P = 0.38) were not responsible for the heterogeneity in the ORs for MetS in RA patients, compared to healthy controls, but mean age (P = 0.03) and diagnostic criteria (P = 0.04) could be considered sources of heterogeneity. Hence, subgroup analysis was undertaken based upon the diagnostic criteria.
Discussion
The present study found a MetS prevalence of 30.65% among RA patients, but this rate ranged from 14.32% to 37.83%, depending upon the MetS definition used. The relatively high degree Worldwide prevalence and risk of metabolic syndrome in rheumatoid arthritis patients III, IDF and AACE) the prevalence of MetS in RA patients varied from 24.6 to 30.7% [26] . Finally, the results of a case-control study in 2013 showed that the frequency of MetS in RA patients and the control group were 30% versus 39% (respectively) when using the ATP III definition and 35% versus 40% (respectively) when using the IDF [27] definition. Therefore, it appears that some of the variation in the prevalence reported are to do with i) a lack of definition clarity, with many different criteria in the existing definitions, ii) different and multiple phenotypes included in each definition of MetS, and iii) the lack of consistency in the number of components required by each definition.
However, prevalence rates also vary widely even when comparing studies that have used the same criteria. For example, using the NCE/ATP definition, Dessein et al. reported a MetS prevalence of 19% among 74 RA patients [28] , while a separate study using the same definition reported a prevalence rate of 42% in those with long standing RA and 30% in those recently diagnosed with RA [29] . Further, in a study of 107 female RA patients a MetS prevalence of 18.7% [30] was reported, but using the same definition Crowson et al. reported the prevalence to be 33% [31] . Therefore, it is likely that other factors related to the characteristics of the study population, such as: genetic, ethnic, cultural, demographic, socioeconomic and clinical factors, also affect the prevalence. Thus, studies conducted using different populations are critical in order to identify other factors related to MetS.
In this study the risk of MetS in RA patients was 45% higher than that in the healthy control group (OR = 1.45; 95% CI: 1.20-1.75). The OR found in the present study is considerably higher than that reported in a meta-analysis of 12 studies in 2013, which reported an OR of 1.24 (95% CI, 1.03-1.50) [11] . Furthermore, Karvounaris et al. found prevalence of MetS to be similar in RA patients (44%) to their control population (41%), but they also found a relationship between disease activity and the presence of MetS [32] . It is also worth mentioning that several studies have not reported any association between RA and MetS [33, 34] .
When we assessed the individual components of MetS (FBS, HDL, BP, Triglyceride, WC), a high WC had the highest prevalence, while the lowest prevalence was high FBS. These findings are consistent with a cross-sectional study by Zafar et al., which found that high FBS (21.9%) was the least prevalent component, while a high WC (46.1%) was the most prevalent component [35] . Furthermore, a study of 200 rheumatoid arthritis outpatients reported that the prevalence of a high WC was 74.8% in female patients and 60.4% in male patients, while the prevalence of high FBS were 30.6% and 26.4% in female and male patients, respectively [32]. In another study, blood pressure, hypoglycemia and HDL had prevalence's of 35.9%, 22.95 and 68.9%, respectively [36] . Therefore, it seems that in most studies a high WC is the most prevalent MetS component and targeting preventative measures at this may considerably reduce the risk of developing MetS.
Advantages
The present study has a number of advantages over the previous meta-analysis, including: 1) All of the published studies were included in this meta-analysis.
2) The prevalence of metabolic syndrome was investigated in RA patients from across the world. 3) This study reported the prevalence of MetS in RA patients based upon eight separate definitions. 4) This paper included both comparative cross-sectional and cross-sectional studies. 5) The odds ratio for metabolic syndrome was pooled across a large number of studies.
Limitations
1) Several countries have not assessed the prevalence of MetS in RA patients and therefore data from those countries could not be presented in this study.
2) The crude (unadjusted) odds ratio for MetS in RA patients was reported, as different studies used different set(s) of confounders.
Conclusion
The prevalence of MetS in RA patients was relatively high, but did not vary significantly by gender. According to the high prevalence of MetS in RA patients and the high risk of it, monitoring and testing for metabolic syndrome in these patients is clearly recommended. As the most important component of metabolic syndrome was found to be a high WC, it is clearly important to pay more attention to patient nutrition and weight loss. Finally, mean age and the diagnostic criteria used to diagnose MetS were identified as sources of heterogeneity in the estimated risk of MetS. 
Supporting information
Author Contributions
Conceptualization: SS JH.
Data curation: JH SS.
Formal analysis: SS NK.
Investigation: JH SS MAM MK NI EA AAH RP NK.
Methodology: SS NK MAM.
Project administration: JH SS.
Software: JH NK SS.
Supervision: SS.
Validation: SS. 
